Louis S. Constine

Louis S. Constine, M.D. is a Professor and Philip Rubin Professor of Radiation Oncology at the University of Rochester Medical Center's School of Medicine and Dentistry. He is a radiation oncologist with clinical and scientific expertise in lymphomas, sarcomas, all pediatric malignancies, and cancer survivorship, particularly focusing on the acute and chronic effects of chemotherapy and radiation therapy on normal tissues. Dr. Constine is actively involved in multiple national and international cancer research groups and is currently accepting new patients at the Wilmot Cancer Center in Rochester, NY.

• MD from Johns Hopkins University School of Medicine (1973)
• Residency in Radiation Oncology, Stanford University Medical Center (1978-1981)
• Fellowship in Pediatric Hematology-Oncology, Seattle Children's Hospital (1976-1978)
• Residency in Pediatrics, Stanford University Medical Center (1975-1976)
• Residency in Pediatric Genetics, UCSF Medical Center Moffitt-Long Hospitals (1973-1975)

Dr. Constine's research primarily focuses on the long-term effects of radiation therapy in pediatric cancer survivors, with special emphasis on normal tissue complications. His work spans radiation dosimetry, late effects management, and survivorship guidelines development. He has been instrumental in establishing international standards for monitoring and preventing radiation-induced complications in childhood cancer survivors through his leadership in the Pediatric Normal Tissue Effects in the Clinic (PENTEC) initiative. His research has significantly contributed to understanding the dose-volume relationships for various normal tissues in children receiving radiation therapy.

His recent publications (2024-2025) demonstrate a strong focus on comprehensive reviews of late effects in childhood cancer survivors through the PENTEC initiative, covering multiple organ systems including thyroid, kidney, metabolic syndrome, neurocognitive effects, and more. His work also includes clinical trials for pediatric Hodgkin lymphoma, innovative approaches to radiation therapy delivery (such as audiovisual immersion techniques), and international collaborations developing standardized surveillance guidelines for cancer survivors. The breadth of his publications shows his leadership in translating research findings into practical clinical guidelines for long-term follow-up care.

Dr. Constine has received numerous prestigious awards throughout his career, reflecting his contributions to both clinical care and research:

• Educator of the Year (2018, 2011)
• America's Most Honored Professionals--Top 1% (2017)
• Albert Nelson Marquis Lifetime Achievement Award (2017-2018)
• Philip Rubin Professor of Radiation Oncology and Pediatrics (2013)
• Patient- and Family-Centered ICARE High Performance Award (2012-2013)
• Multiple teaching awards including the Philip Rubin-Mayer Mitchell Teaching Award (2005, 2001, 1997)
• America's Top Doctors for Cancer (2007-2017)

Dr. Constine serves as the Radiation Chair of the Lymphoma Committee in the Southwest Oncology Group and holds leadership positions in multiple national and international organizations focused on childhood cancer survivorship. He chairs the Pediatric Quantitative Analysis of Normal Tissue Effects in the Clinic ASTRO/AAPM initiative and serves on the Children's Oncology Group Late Effects Steering Committee. His grant funding includes an ROI evaluating long-term cardiac toxicities in Hodgkin lymphoma survivors and membership on the steering committee for the NCI-supported Childhood Cancer Survivorship Study. His international work includes participation in United Nations task forces on radiation effects in children and International Atomic Energy Agency initiatives for pediatric radiation oncology in low-income countries.

Dr. Constine leads the Pediatric Normal Tissue Effects in the Clinic (PENTEC) initiative, an international collaboration that has produced numerous comprehensive reviews on radiation dose-volume-response relationships for children with cancer. Through this work, he has established himself as a world leader in understanding and mitigating the late effects of radiation therapy in pediatric cancer survivors. His collaborative efforts span multiple institutions and countries, focusing on developing evidence-based guidelines for long-term follow-up care of childhood cancer survivors.